NCT02954094 2026-04-17
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Target PharmaSolutions, Inc.
Active not recruiting
Clinical Trials
13 trialsNCT03778957 2026-04-15
EMERALD-1
AstraZeneca
Phase 3 Active not recruiting
NCT04145141 2026-04-14
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
National Institutes of Health Clinical Center (CC)
Active not recruiting
NCT06091930 2026-04-14
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT02381561 2026-04-13
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05211323 2026-04-13
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06679985 2026-04-13
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Active not recruiting
NCT05301842 2026-04-07
EMERALD-3
AstraZeneca
Phase 3 Active not recruiting
NCT03408665 2026-03-30
STEREOLIVER
Centre Oscar Lambret
Phase NA Active not recruiting
NCT05063565 2026-03-27
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT05622136 2026-03-27
STRAT-aHCC
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT03937830 2026-03-24
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04008797 2026-03-24
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting